Daniel Bauer, MD, PhD, is a physician-scientist whose research focuses on functional genomics to dissect determinants of blood cell development and disease and develop innovative therapies.
Displaying 31-40 of 70 results matching:
Strategies to bar the coronavirus (COVID-19) from entering cells — thereby preventing infection and averting transmission of the virus — are among the most promising treatment approaches to COVID-19.
Dana-Farber/Boston Children’s physicians have implemented crucial testing protocols during this unusual time, with a focus that children with cancer need life-saving treatments even in the setting of a viral pandemic.
Past recipients with ties to Dana-Farber/Boston Children’s include Joanne Wolfe, MD, MPH (2016); Scott A. Armstrong, MD, PhD (2014); David Williams, MD (2006); and Stuart Orkin, MD (2003).
The clinical trial will investigate the effectiveness of a combination of two oral drugs targeting the DNA damage response pathway.
Dr. Baird specializes in the care of children with neurological disorders of the brain and spine, with specific expertise in brain and spinal cord tumors, cerebrovascular malformations, and skull base neurosurgery.
Daphne Haas-Kogan, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, will receive a research grant totaling $600,000 over three years for “Dependence of DIPGs on DNA polymerase q for DNA repair defines a new therapeutic target.”
Launched by the King Faisal Foundation (KFF) and granted for the first time in 1979, the King Faisal Prize (KFP) recognizes the outstanding works of individuals and institutions in five major categories: Service to Islam, Islamic Studies, Arabic Language and Literature, Medicine, and Science.
Boston magazine has named at least 25 faculty members of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center to its annual "Top Doctors" guide.